Xavier Montalbán

Research interests

Publications

• Locus for severity implicates CNS resilience in progression of multiple sclerosis

  Nature · 2023 · https://doi.org/10.1038/s41586-023-06250-x

• Multiple sclerosis progression: time for a new mechanism-driven framework

  The Lancet Neurology · 2022 · https://doi.org/10.1016/s1474-4422(22)00289-7

• 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

  The Lancet Neurology · 2021 · 10.1016/s1474-4422(21)00095-8

• 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

  The Lancet Neurology · 2021 · 10.1016/s1474-4422(21)00095-8

• Ofatumumab versus Teriflunomide in Multiple Sclerosis

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917246

• Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

  Science · 2019 · https://doi.org/10.1126/science.aav7188

• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30239-x

• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30238-8

• Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30137-1

• ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

  Multiple Sclerosis Journal · 2018 · https://doi.org/10.1177/1352458517751049

• ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis

  European Journal of Neurology · 2018 · https://doi.org/10.1111/ene.13536

• Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

  The Lancet Neurology · 2017 · https://doi.org/10.1016/s1474-4422(17)30470-2

• Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica

  Journal of Neurology Neurosurgery & Psychiatry · 2016 · https://doi.org/10.1136/jnnp-2015-312601

• MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

  The Lancet Neurology · 2016 · 10.1016/s1474-4422(15)00393-2

• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1606468

• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1601277

• Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

  Multiple Sclerosis Journal · 2015 · https://doi.org/10.1177/1352458514568827

• Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event

  PLoS ONE · 2014 · https://doi.org/10.1371/journal.pone.0090509

• Defining the clinical course of multiple sclerosis

  Neurology · 2014 · https://doi.org/10.1212/wnl.0000000000000560

• Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

  The Lancet · 2013 · https://doi.org/10.1016/s0140-6736(12)62190-4

• Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

  The Lancet Neurology · 2013 · https://doi.org/10.1016/s1474-4422(13)70102-9

• Treatment of cognitive impairment in multiple sclerosis: position paper

  Journal of Neurology · 2012 · https://doi.org/10.1007/s00415-012-6678-0

• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  Annals of Neurology · 2011 · https://doi.org/10.1002/ana.22366

• Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

  Nature · 2011 · https://doi.org/10.1038/nature10251

• Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa0907839

• Differential diagnosis of suspected multiple sclerosis: a consensus approach

  Multiple Sclerosis Journal · 2008 · 10.1177/1352458508096878

• Multiple Sclerosis Severity Score

  Neurology · 2005 · https://doi.org/10.1212/01.wnl.0000156155.19270.f8

Current projects

No projects listed.